Interim Reports

Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.

Sales more than doubled in 2021/22, compared to previous financial year.

Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.

The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.